|D014777||Virus Diseases NIH||0.11|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
This study is a randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19
Description: The ordinal scale is an evaluation of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Not hospitalized, no limitations on activities; 2) Not hospitalized, limitation on activities and/or requiring home oxygen; 3) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 4) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5) Hospitalized, requiring supplemental oxygen; 6) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 7) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 8) Death.Measure: The proportion of patients with a two-point change using the 8-category ordinal scale Time: Day 14 from baseline
Description: All-cause mortality post baselineMeasure: All-Cause mortality Time: Day 28 and Day 60 post baseline
Description: Time to a 2-point clinical change differenceMeasure: Time to a 2-point clinical change Time: Up to 60 days post baseline
Description: Duration of hospitalizationMeasure: Hospitalization Time: Up to 60 days post baseline
Description: For subjects who are on ECMO or mechanical ventilation at Day 1Measure: Duration of ECMO or invasive mechanical ventilation Time: Up to 60 days post baseline
Description: For subjects who are in ICU at Day 1Measure: Duration of ICU stay Time: Up to 60 days post baseline
Description: Time to SARS-CoV-2 negative by reverse transcriptase-polymerase chain reaction (RT-PCR)Measure: SARS-CoV-2 negative Time: Up to 60 days post baseline
Description: Proportion of patients with negative oropharyngeal or nasopharyngeal swab for SARS-CoV-2 by quantitative RT PCR on days 5, 10, 14, 21, and 28 after starting treatmentMeasure: Negative oropharyngeal or nasopharyngeal swab Time: Up to 28 days post baseline
Description: Proportion of subjects with serious adverse eventsMeasure: Serious adverse events (SAEs) Time: Up to 60 days post baseline
Description: Proportion of subjects who discontinue study drug due to adverse eventsMeasure: Discontinuation due to adverse events Time: Up to 60 days post baseline
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports